As a clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to optimize and develop drug candidates to treat ulcerative colitis and other inflammatory diseases (ABX464), HIV (ABX464), and liver cancer (ABX196). Our mission is to utilize Abivax’s drug development platforms to bring innovative and effective solutions to patients in these therapeutic areas with significant unmet needs.
We have one key focus: To contribute towards the global effort to combat antibiotic resistance. Antibiotic resistance is widespread and growing exponentially. Allecra’s contribution is to develop new treatments which overcome emerging resistance mechanisms, thereby saving lives of patients whose infections may otherwise be inadequately treated
Allecra has a novel β-lactamase inhibitor in Phase 2 clinical development. By inhibiting β-lactamases Allecra’s new medicine directly tackles emerging resistance mechanisms of certain hard-to-treat bacteria. These resistance mechanisms are often found in hospital-acquired Gram-negative bacterial infections, and are of particular concern to doctors, healthcare providers, to patients and their families and to governments around the world
Allecra Therapeutics is situated in the BioValley Life Sciences region in the Upper Rhein valley whichencompasses northwest Switzerland, southwestern Germany and the Alsace region of France http://allecra.com/
Anima Biotech, Inc.
Anima Biotech is advancing Translation Control Therapeutics, the first and only platform for the discovery of small molecule drugs that specifically control mRNA translation as a new strategy against hard and undruggable targets in many diseases.
Anima’s proprietary technology enables visualization and monitoring of target protein translation via pulses of light emitted by ribosomes. The fully automated high-throughput screening system discovers small molecules that modulate the light, as they decrease or increase the target protein’s production. The platform integrates proprietary technologies in biology, bioinformatics, image analysis, big data analysis and artificial intelligence algorithms in a cloud computing software architecture.
Anima is developing an internal pipeline across multiple therapeutic areas with high unmet need and hard targets. Current programs are in Fibrosis (inhibiting the synthesis of Collagen type I), Viral infections (Respiratory Syncytial Virus – interfering with viral protein synthesis), Oncology (C-Myc translation inhibitors) and Huntington's disease (monitoring mutant Huntingtin translation pausing).
Anima’s Translation Control Therapeutics platform is strategically designed for partnering with Pharma. The power of Anima’s approach was solidified with a $1B+ collaboration with Lilly for the discovery and development of translation inhibitors of several targets. Anima’s technology has been further validated by 5 granted patents, 14 peer reviewed publications and 17 scientific collaborations.
APEIRON is a privately-held European biotech company based in Vienna, Austria, focused on the discovery and development of novel cancer immunotherapies. APEIRON received EU marketing approval for APN311 (Dinutuximab beta, Qarziba®) in May 2017 for the treatment of pediatric neuroblastoma patients and out-licensed global, exclusive rights to this product to EUSA Pharma Ltd. APEIRON now leverages its proprietary master checkpoint blockade mechanism to enable the human body’s natural defense mechanisms to fight tumors. APEIRON’s lead clinical program APN401 is a first-in-class autologous cellular therapy to enhance immune reactivity via an intracellular immune master checkpoint, Cbl-b. APEIRON’s key projects and technologies are bolstered by a strong patent portfolio with broad territorial coverage. APEIRON’s development expertise is validated through partnerships with leading global pharmaceutical companies and academic institutions.
BAYOOMED is the medical software division of BAYOONET Inc. Here we combine medical professional know-how with our software development expertise. We serve more than 800 clients from the pharmaceutical and medical technology sector, and we specialize in the development of medical (standalone) software and medical apps (iOS, Android, Windows 8) in accordance with IEC 62304, ISO 13485, ISO 14971 and EN 62366. We support our clients through all product lifecycle phases:
Based on its insights in immunology, cancer biology and antibody biology, BioInvent aims to develop cancer immunotherapies to improve the quality of life for cancer patients.
BioInvent's current operational activities are focused on:
Progressing and expanding the clinical development of its lead antibody BI-1206 for treatment of haematological cancers.
Developing pre-clinical first-in-class antibodies targeting tumour-associated myeloid cells in collaboration with Pfizer.
Advancing three compounds into clinical programs in solid cancer: anti FcγRllB antibody in combination with anti-PD1 antibody – projected start phase l/lla in H1 2019; BI-1607 (an anti FcγRllB antibody) in combination with check point inhibitor – projected start phase l proof of concept trial in H2 2019; BI-1808 (anti-“EmergingTNFRS” antibody), as single agent and in combination with anti-PD1 antibody – projected start phase l in H1 2020. Advancing its pre-clinical Treg immuno-oncology programmes identifying antibodies to novel targets and pathways, as well as differentiated antibodies with new mechanisms-of-action to validated targets. Intensify the collaboration with Transgene to start the development of oncolytic virus (OV) candidates encoding a validated anti-CTLA-4 antibody sequence - potentially with additional transgenes - aimed at treating solid tumors. Developing TB-403, in collaboration with Oncurious, as a potential treatment for paediatric brain cancers.
The Swiss biopharmaceutical company BioVersys focuses on research and development of small molecules which switch off drug resistance against existing antibiotics. With the company’s award-winning TRIC technology (Transcriptional Regulator Inhibitory Compounds) it will be possible to restore the efficacy of established antibiotics. By this, BioVersys addresses the high medical need for new treatments against life-threatening bacterial infections that emerged in recent years due to the resistance of bacterial strains against existing antibiotics. BioVersys' compounds will be used in combination with existing antibiotics, thereby renewing efficacy as well as intellectual property for the established drug. The current research focus is Nosocomial Infections (hospital infections) and Tuberculosis. In collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille, BioVersys is developing a preclinical candidate against tuberculosis.
Over the last three decades, the number of newly approved antibiotics has steadily declined. At the same time, resistance against existing drugs has become more and more prevalent. Antibiotic resistance is recognized by the WHO as a major public health concern as exemplified by its recently released global report (click HERE for access). BioVersys has a pipeline of promising compounds that address this concern. The company is currently at preclinical stage with proof-of-concept in animals already demonstrated.
We are a group of individuals who know that there is a better way to develop drugs. Our business model and broad, science-based portfolio has attracted some of the brightest minds in drug development. Our team brings together more than 300 years of pharmaceutical industry experience.
Cue Biopharma is committed to bringing selective immune modulation to patients through our Cue Biologics platform. Our talented scientists are led by an experienced management team and supported by leading scientific and clinical advisors with deep expertise in the design and clinical development of protein biologics to treat cancer and autoimmune diseases. Together, we are developing novel, targeted therapies aimed at overcoming many of the challenges facing prevailing immunotherapeutics. We are headquartered in Kendall Square, Cambridge, MA.
EpimAb Biotherapeutics is a privately owned biopharmaceutical R&D company based in Shanghai with a proprietary, unique and efficient technology called FIT-Ig® (Fabs-In-Tandem Immunoglobulin) that generates bispecific molecules with antibody-like properties. With this innovative platform, EpimAb is creating a potentially game-changing pipeline of its own novel bispecific antibody therapeutics focused around immuno-oncology and other areas of high value to patients.
Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary spherical nucleic acid (SNA™) architecture is designed to unlock the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address inflammatory diseases, genetic disorders and oncology. Exicure is based outside of Chicago, IL.
SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.
SNA™ technology originated in the lab of Professor Chad A. Mirkin at the Northwestern University International Institute for Nanotechnology. Exicure's intellectual property portfolio includes over 135 pending patent applications and over 60 allowed or issued patents. These filings impact numerous jurisdictions worldwide, and they cover a range of inventions, including fundamental nanoparticle manufacturing breakthroughs and numerous application-specific improvements.
Gadeta B.V. is a Research & Development company established in 2015 which focusses on the development of innovative immunotherapies for cancer. The work of the company is based on the groundbreaking discoveries regarding the role of γδ T cell receptors (TCRs) in the broad recognition of both hematological and solid tumor cells and their potential use for the treatment of advanced malignancies as discovered by Prof. Dr. Jürgen Kuball, co-founder of Gadeta, at the University Medical Centre Utrecht (UMCU), The Netherlands.
The Gadeta office and laboratory is located in the Bio Incubator next to the UMCU and collaborates with top-tier international scientists to achieve its goals.
Hookipa Pharma Inc. is a clinical-stage company developing medicines to prevent and cure infectious diseases and cancer. With this goal in mind, we have created unique and cutting-edge technologies to reprogram and stimulate the immune system.
Our arenavirus technologies, Vaxwave®* and TheraT®*, are antigen delivery vehicles, engineered to trigger immune responses to combat infections or cancers. Vaxwave®, a replication-deficient viral vector, and TheraT®, a replication-attenuated vector, induce potent antigen CD8 T cell responses in vivo, while also generating potent pathogen-neutralizing antibodies. TheraT®-induced CD8 T cells reach frequencies and potencies in response to tumor antigens that match or exceed those observed following adoptive T cell therapy. Over the last few years several personalized T cell mediated therapies (e.g. TILs, ACT, TCR) have demonstrated clinical success ex vivo but replicating this success in vivo has proven difficult. Hookipa’s viral vectors are “off-the-shelf” and naturally reprogram the immune system, stimulating an increase in CD8 T cells against a target of choice. In practice, our vectors can be delivered anywhere, intramuscularly, intravenously, or directly into a tumor, according to the needs of the patient or the type of the cancer. Our vectors target dendritic cells which stimulate T cells to fight the disease. These stimulated T cells then naturally attack the infectious disease or cancer target. In immuno-oncology, this mechanism enables us to fight solid tumors systemically, both primary tumors and secondary tumors that have spread (metastasized). Vaxwave® and TheraT® can both be administered repeatedly and maintain their efficacy as they carry glycan shields, which prevents neutralizing antibodies from deactivating them. Other vector systems lose their efficacy after one injection. Vaxwave® and TheraT® do not need to be patient-specific and do not require complicated ex-vivo cell handling and engineering. They are still able to reprogram the immune system and stimulate levels of antigen-specific CD8 T cells previously only possible using ex vivo approaches.
Imcyse is pioneering the development of a new class of active, specific immunotherapeutics: ImotopesTM. Imcyse’s new technology platform is based on the discovery of modified synthetic peptides to block the immune processes causing immune-mediated diseases. Imcyse’s ImotopesTM offer the possibility to cure severe chronic diseases for which there is no satisfactory therapeutic alternative. The technology can also prevent the immunogenic responses that weaken the efficiency of chronic therapies.
Our vision is to become a major player in active specific immunotherapy for the curative treatment of autoimmune and allergic diseases.
Immune System Key Ltd. (ISK) is a privately held company that was founded in 2005 by Prof. Uziel Sandler and Dr. Yoram Devary.
The company is engaged with developing of its drug candidate Nerofe TM. Nerofe TM acts through a novel MOA that serves as the basis for the personalized anti-cancer immunotherapy technology developed by ISK Ltd. Our anti-cancer immunotherapy technology synergizes well with anti-PD1/PDL1 technology.
The company has successfully finished Phase1 trial and is now aiming three Phase 2 clinical trials in the USA.
NerofeTM was granted by the FDA with orphan drug designation for AML treatment. The company holds 3 worldwide patents on the molecule and applications.
We are looking for collaborations and investments to keep on developing our anti-cancer technology
InCarda Therapeutics, Inc. is a privately-held, clinical-stage biopharmaceutical company pioneering a novel approach of treating cardiovascular conditions by the inhalation route. The advantage of inhalation is that it delivers medicine in the “first pass” to cardiac tissue, presenting a small, but effective dose of drug directly to affected regions of the heart. This permits rapid-onset, lower off-target tissue exposure of the drug, lower continued/prolonged exposure to cardiac tissue and, more importantly, can be patient self-administered anywhere PAF episodes may occur.
The lead product under development is an inhaled therapy to treat paroxysmal atrial fibrillation (PAF), a widespread atrial arrhythmia. InCarda employs a de-risked approach by using approved drugs with a long history of efficacy and safety in a new dosing paradigm.
We are a team of highly-experienced, passionate teammates who have a strong track record of development. We are also supported by a world-class group of experts and advisors.
Medherant is developing a pipeline of products for pain and neurology indications, based on its next-generation TEPI-Patch® transdermal drug technology. The company also formulates client molecules in this unique solvent-free drug-in-adhesive system. Medherant was founded by Professor David Haddleton and the University of Warwick to develop and commercialise novel technologies for delivery of drugs via the skin using their world-leading expertise in bioadhesives and polymer chemistry. The Company is based on the University of Warwick Science Park in Coventry (UK). Medherant has received investment from Mercia Fund Management and others. Delivery of drugs using patches that are applied to the skin provides better control of the dose than with gels, ointments and creams. However, the currently available technologies limit the types of drugs that can be used and the quantities that can be loaded into the patch. Medherant’s TEPI Patch® is formulated with a novel polymer adhesive which has been exclusively licensed from Bostik. The drug to be delivered is mixed with the adhesive to form a thin, flexible, single layer patch. One of the key advantages of the TEPI Patch® technology is that a greater quantity of drug can be blended with the adhesive. This enables lower potency drugs to be formulated as a patch and provides the opportunity to increase the dose of drugs already administered via a patch or reduce patch size. The TEPI Patch® also provides a better experience for the user as it does not leave a residue around the patch – referred to as ‘cold flow’ – and has excellent adhesion whilst still being easy and painless to remove. Medherant is developing its own TEPI Patch® products in the fields of pain management and CNS disorders, and is working with third parties to apply the technology to their drugs. The Company expects to earn revenues from licensing products that it has developed to pharmaceutical companies and through collaborative development projects leading to potential technology licences.
Our pipleline includes drugs aimed at first-in-class targets that are synthetically lethal with the loss of the following metabolic enzymes: Fumarate Hydratatse (FH), Succinate Dhydrogenase (SDH) and Methylthioadenosine Phosphorylase (MTAP). Although SDH and FH are “housekeeping genes”‘ with key bioenergetic roles, they are also known to be tumor-suppressing genes. The loss of their function results in cancer, specifically in the kidney and in the GI tract. MTAP function is lost in about 15% of all cancers. This percentage grows to 55% of Glioblastoma and up to 25% Pancreatic Adenocarcinoma, two especially aggressive and hard to treat cancers.
Our vaccines are designed to induce protection against early transmission and infection, focusing both on the mucosal immune response as a first-line defense and the systemic humoral (blood) immune response, which, for some pathogens, may be essential for the development of an effective prophylactic vaccine. Our unique approach has resulted in the development of a rich pipeline of vaccine candidates for HIV-1/AIDS, intra nasal Influenza, Malaria, Chikungunya and the Respiratory Syncytial Virus (RSV) vaccine. Our delivery platform is being validated through partnership with leading pharmaceutical or research organisations, including Sanofi, PATH-MVI and the Bill and Melinda Gates Foundation. Mymetics Corporation (OTCQB: MYMX) is a Swiss based biotechnology company, with a Research Lab in the Netherlands. The company is registered in the US and trades on the OTCQB. www.mymetics.com
ORYZON GENOMICS S.A. [BME:ORY]
Oryzon is a public clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics.
From its founding in 2000 through 2008, the company focused its efforts in grow¬ing a functional genomics platform business model, In 2008, with the acquisition of Crystax Phar-maceuticals, we started our drug discovery programs in oncology and neurode¬generative diseases. Our business model is to develop our proprietary drug candi¬dates till mid clinical stage, at which point it is decided on a case-by-case basis to either keep the development in-house or to partner or outlicense the compound for late stage development and commercialization.
Oryzon is listed on the Spanish Stock Exchange since December 2015 (ORY, ISIN Code: ES0167733015). In the period 2015-2016, the company raised €32M, with ad¬ditional Pipes in 2017 (€18.2M) and 2018 (€13M) where the company incorporated specialized investors from US and Europe. The company has a broad and growing portfolio, with two compounds in clinical trials, Iadademstat (ORY-1001), a highly potent and selective LSD1 inhibitor that has been granted orphan-drug status by EMA, in Phase IIA in oncology, and Vafidem¬stat (ORY-2001), a LSD1/MAO-B inhibitor , also in Phase IIa, dual for the treatment of mild to moderate Alzheimer’s disease, multiple scle¬rosis. Vafidemstat is al being explored in a basket trial to treat aggressiveness in psychiatric conditions like ASD, ADHD and BLP and other neurodegenerative diseases. The company has another compound ready to start Phase I, ORY-3001, a selective LSD1 inhibitor for the treatment of non-oncological diseases, and additional earlier programs in other cancer indications.
From 2014 to 2017 the company had a collaboration with Roche relating to our lead oncology program and received +$23M. This asset is now being developed by Oryzon. The company has also obtained competitive US and European grants in the amount of €8M to support the development of Vafidemstat (ORY-2001) since the start of our CNS research. The company has a seasoned executive management with vast experience in the industry.
Founded in April 2014 in Grenoble (France) as a spin-off of the French Blood Bank (Etablissement Français du Sang, EFS), PDC*line Pharma is a Belgian-French biotech company that is developing a novel class of off-the-shelf cancer immunotherapies based on a proprietary Plasmacytoid Dendritic Cell line (PDC*line) pre-loaded with peptides that are derived from target tumor antigens. Based on a robust preclinical package and a first-in-human phase Ib feasibility study in melanoma, PDC*line Pharma is focusing on lung cancer with a new candidate in early clinical development (PDC*lung) and neoantigens (PDC*Neo). PDC*line Pharma comprises a team of highly skilled professionals based in Liège (Belgium) and Grenoble (France). PDC*line Pharma comprises a team of 17 persons, has raised nearly €15 M in equity and non-dilutive funding.
Perora GmbH, a biotechnology company, develops a polymer-based fat-binding medical device as a platform for weight management and obesity treatment. The company was incorporated in 2013 and is based in Heidelberg, Germany.
Pharmaleads aims to provide patients suffering from severe chronic and acute pain with improved pain relief without the side effects associated with other classes of analgesics.
Based on years of experience in the design of highly potent and specific inhibitors of enkephalinases, Pharmaleads has developed a new class of analgesics called DENKIs (Dual Enkephalinases inhibitors). These small molecules are able to provide patients with local and sustainable pain relief.
Pharmaleads’ DENKIs are first-in-class drugs with a novel mechanism of action tackling pain by using endogenous enkephalins, natural peptides that specifically bind to pain-related opioid receptors to naturally modulate pain without the side effects observed with exogenous opioid drugs that also bind to other opioids receptors, not involved in pain control, triggering multiple side effects.
Pharmaleads believes its products can change the lives of the many patients who are in need of improved treatment options for their chronic and/or acute pain, and could offer healthcare providers with an improved pain management option that helps address the opioid epidemic.
We aim to become a leading pharma company focused on antibiotics and specialty diseases
We are a clinical stage biopharmaceutical company based in Allschwil, Switzerland, and are focused on the discovery and development of antibiotics and other specialty pharma products for severe or life-threatening diseases.
Polyphor was founded in 1996 and is a clinical stage biopharmaceutical company based in Allschwil, Switzerland, near Basel. It focuses on the development of macrocycle drugs that address antibiotic resistance and improve therapy outcomes in cancer.
Silence Therapeutics develops a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells.
Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence’s proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.
We develop innovative therapies for the treatment of cancer and other significant diseases
Symphogen is a clinical-stage antibody oncology-focused company with a differentiated product pipeline and significant commercial opportunities. Our pre-clinical and clinical pipeline is well suited for a precision-medicine approach by addressing well-defined, biomarker-selected patient populations.
Two To Biotech Ltd. is a privately held biotech company established in 2007 engaged with the discovery of novel human peptide hormones and development of mAb against novel human targets. The peptide hormones we have discovered are for treatment of oncology indications and some for treatment of diabetes and other metabolic disorders.
The different peptide hormones were discovered by using the company's revolutionary technology platforms for the discovery of novel human peptide hormones, receptors, and enzymes. Our technologies are the first in the world that allows 3D-protein structure screening of the human genome, so we are not limited to any sequence. This approach allowed us to identify many novel proteins never discovered.
We are looking for collaborations and investments to discover and develop new targets in the area of immune regulation of cancer, regulation of body weight and metabolism.
UGISense AG is a biotech company dedicated to developing new and innovative antisense therapeutic agents in collaboration with partners from the industry and academia. The developments are made on the basis of a proprietary platform technology, i.e. the UgimeresTM. The company, which was first established in 2016, is being financed by private investors and has been accredited by the Federal Office of Economics and Export Control (BAFA) (within the scope of their Funds for Venture Capital program).
VAXIMM is a privately held, clinical stage, Swiss/German biotech company developing oral T-cell immunotherapies for patients suffering from cancer.
VAXIMM’s technology is based on first-in-class oral T-cell activators using modified attenuated bacteria that can be readily adapted to target a wide range of cancer-related antigens.
The Company’s lead product candidate, oral VXM01, activates killer T-cells targeting tumor vasculature and certain immune-suppressive cells, thereby increasing immune cell infiltration in solid tumors.
VXM01 is currently in clinical development for several tumor types, including pancreatic, colorectal and brain cancer.
The Company has several additional product candidates at various stages of preclinical development targeting a variety of tumor targets and neoantigens.
VAXIMM has a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc. to evaluate avelumab, a human anti-PD-L1 antibody, in combination with VXM01 in glioblastoma and colorectal cancer. The Company also has entered into a collaboration agreement with China Medical System Holdings (CMS), granting CMS full rights in China and other Asian countries (excluding Japan) to VAXIMM’s existing programs.
VAXIMM’s investors include BB Biotech Ventures, BioMed Partners, CMS, M Ventures and Sunstone Capital.
VAXIMM AG is headquartered in Basel, Switzerland. Its wholly owned subsidiary, VAXIMM GmbH, located in Mannheim, Germany, is responsible for the Company’s development activities.